TY - JOUR
T1 - Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients
AU - Boogerd, Leonora S.F.
AU - Boonstra, Martin C.
AU - Beck, Ann Jean
AU - Charehbili, Ayoub
AU - Hoogstins, Charlotte E.S.
AU - Prevoo, Hendrica A.J.M.
AU - Singhal, Sunil
AU - Low, Philip S.
AU - van de Velde, Cornelis J.H.
AU - Vahrmeijer, Alexander L.
N1 - Funding Information:
The authors gratefully acknowledge R. Keyzer for his support and immunohistochemical expertise and Prof. Dr. V.T.H.B.M. Smit, pathologist, for his contribution to the analysis of the stained tissues. In addition, we would like to thank the research group at the University of Pennsylvania Perelman School of Medicine for providing us with an image of intraoperative FRa-targeted NSCLC detection.
PY - 2016
Y1 - 2016
N2 - Folate receptor alpha (FRα) is known to be upregulated in a variety of cancers, including non-small cell lung cancer (NSCLC) and breast cancer. To ensure reliable implementation of diagnostic- and therapeutic agents, concordance of FRα expression between biopsy, primary tumor and metastases is important. Using immunohistochemistry (Mab 26B3.F2) these concordances were investigated in 60 NSCLC and 40 breast cancer patients. False positivity of FRα expression on breast and lung cancer biopsies was limited to less than 5%. In NSCLC, FRα expression was shown in 21/34 adenocarcinomas and 4/26 squamous cell carcinomas (SCC). Concordance of FRα expression between biopsy and primary tumor was achieved in respectively 83% and 91% of adenocarcinomas and SCCs. Approximately 80% of all local and distant metastases of NSCLC patients showed concordant FRα expression as their corresponding primary tumor. In breast cancer, FRα positivity was shown in 12/40 biopsies, 20/40 lumpectomies and 6/20 LN metastases, with concordance of 68% between biopsy and primary tumor and 60% between primary tumor and LN metastases. In conclusion, this study shows high concordance rates of FRα expression between biopsies and metastases compared to primary NSCLC and breast cancers, underscoring the applicability of FRα-targeted agents in these patients.
AB - Folate receptor alpha (FRα) is known to be upregulated in a variety of cancers, including non-small cell lung cancer (NSCLC) and breast cancer. To ensure reliable implementation of diagnostic- and therapeutic agents, concordance of FRα expression between biopsy, primary tumor and metastases is important. Using immunohistochemistry (Mab 26B3.F2) these concordances were investigated in 60 NSCLC and 40 breast cancer patients. False positivity of FRα expression on breast and lung cancer biopsies was limited to less than 5%. In NSCLC, FRα expression was shown in 21/34 adenocarcinomas and 4/26 squamous cell carcinomas (SCC). Concordance of FRα expression between biopsy and primary tumor was achieved in respectively 83% and 91% of adenocarcinomas and SCCs. Approximately 80% of all local and distant metastases of NSCLC patients showed concordant FRα expression as their corresponding primary tumor. In breast cancer, FRα positivity was shown in 12/40 biopsies, 20/40 lumpectomies and 6/20 LN metastases, with concordance of 68% between biopsy and primary tumor and 60% between primary tumor and LN metastases. In conclusion, this study shows high concordance rates of FRα expression between biopsies and metastases compared to primary NSCLC and breast cancers, underscoring the applicability of FRα-targeted agents in these patients.
KW - Biomarker
KW - Diagnosis
KW - Oncology
KW - Pathology Section
KW - Personalized medicine
KW - Targeting
UR - http://www.scopus.com/inward/record.url?scp=84975485143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975485143&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.7856
DO - 10.18632/oncotarget.7856
M3 - Article
C2 - 26943581
AN - SCOPUS:84975485143
SN - 1949-2553
VL - 7
SP - 17442
EP - 17454
JO - Oncotarget
JF - Oncotarget
IS - 14
ER -